Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients With Unresectable Pancreatic Cancer

NCT02336087 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT02336087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02336087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients With Unresectable Pancreatic Cancer
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 14, 2016
Completion date
December 9, 2026
Enrollment
21 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma, stage iii pancreatic cancer ajcc v6 and v7, stage iv pancreatic cancer ajcc v6 and v7, unresectable pancreatic carcinoma